Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005)

Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005)

Author Sader, Helio Silva Autor UNIFESP Google Scholar
Watters, Amy A. Google Scholar
Fritsche, Thomas R. Google Scholar
Jones, Ronald N. Google Scholar
Institution JMI Labs
Universidade Federal de São Paulo (UNIFESP)
Tufts Univ
Abstract Background: Daptomycin is a cyclic lipopeptide with potent activity and broad spectrum against Gram-positive bacteria currently used for the treatment of complicated skin and skin structure infections and bacteremia, including right sided endocarditis. We evaluated the in vitro activity of this compound and selected comparator agents tested against clinical strains of staphylococci and enterococci collected in European medical centers in 2005.Methods: A total of 4,640 strains from 23 medical centers located in 10 European countries, Turkey and Israel ( SENTRY Program platform) were tested for susceptibility by reference broth microdilution methods according to Clinical and Laboratory Standards Institute guidelines and interpretative criteria. Mueller-Hinton broth was supplemented to 50 mg/L Ca++ for testing daptomycin. Results for oxacillin ( methicillin)-resistant staphylococci and vancomycin-resistant enterococci were analyzed separately.Results: Oxacillin resistance rates among Staphylococcus aureus varied from 2.1% in Sweden to 42.5% in the United Kingdom (UK) and 54.7% in Ireland (29.1% overall), while vancomycin resistance rates varied from 0.0% in France, Sweden and Switzerland to 66.7% in the UK and 71.4% in Ireland among Enterococcus faecium (17.9% overall). All S. aureus strains were inhibited at daptomycin MIC of 1 mg/L ( MIC50/90, 0.25/0.5 mg/ L; 100.0% susceptible) and only one coagulase-negative staphylococci strain (0.1%) showed an elevated (> 1 mg/ L) daptomycin MIC value ( 4 mg/ L). Among E. faecalis (MIC50/90, 0.5/ 1 mg/ L; 100% susceptible) the highest daptomycin MIC value was 2 mg/L; while among E. faecium (MIC50/90, 2/4 mg/ L; 100% susceptible) the highest MIC result was 4 mg/ L.Conclusion: Daptomycin showed excellent in vitro activity against staphylococci and enterococci collected in European medical centers in 2005 and resistance to oxacillin, vancomycin or quinupristin/dalfopristin did not compromise its activity overall against these pathogens. Based on these results and those of previous publications, daptomycin appears to be an excellent therapeutic option for serious infections caused by oxacillin-resistant staphylococci and vancomycin-resistant enterococci in Europe.
Language English
Date 2007-04-18
Published in Bmc Infectious Diseases. London: Biomed Central Ltd, v. 7, 9 p., 2007.
ISSN 1471-2334 (Sherpa/Romeo, impact factor)
Publisher Biomed Central Ltd
Extent 9
Origin http://dx.doi.org/10.1186/1471-2334-7-29
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000246362700001
URI http://repositorio.unifesp.br/handle/11600/29669

Show full item record




File

Name: WOS000246362700001.pdf
Size: 289.7Kb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account